Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $151.00 thousand which beat the analyst consensus estimate of $94.17 thousand by 60.35 percent. This is a 3.21 percent decrease over sales of $156.00 thousand the same period last year.